#19 January 2024 Delivering strong and sustained momentum Emma Walmsley, Chief Executive Officer J.P. Morgan Healthcare Conference, San Francisco GSK gsk.com#2Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect", "intend", 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements. Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group's control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D ‘Risk factors' in the Group's Annual Report on Form 20-F for the full year (FY) 2022. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation. A number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in the Q3 2023 earnings release and Annual Report on Form 20-F for FY 2022. All guidance, outlooks, ambitions and expectations should be read together with the guidance, assumptions and cautionary statement in the Q3 2023 earnings release and the 2022 Annual Report. Basis of preparation: On 18 July 2022, GSK plc separated its Consumer Healthcare business from the GSK Group to form Haleon, an independent listed company. Comparative figures have been restated on a consistent basis. Earnings per share, Adjusted earnings per share and Dividends per share have been adjusted to reflect the GSK Share Consolidation on 18 July 2022. GSK 2#3Focus on prevention and treatment, with performance momentum GSK Q3 and 9 months 2023 delivered double digit sales and adjusted operating profit growth 1.2 GSK Strong performances from key products led by outstanding launch of first ever RSV vaccine Arexvy Approvals across Specialty Medicines strengthening new product portfolio Nearly £8 billion of sales in 9 months 2023 from products launched since 20173 and 70% of business now in Vaccines and Specialty Medicines 1. Excluding COVID-19 solutions 2.9m year-to-date 2023 financials 3. New products launched since 2017 delivered £7.8 billion 9m 2023 and include: Zejula, Trelegy, Shingrix, Juluca, Dovato, Duvroq, Rukobia, Blenrep, Cabenuva, Jemperli, Apretude, Arexvy 3#4Delivering on commitments to growth. Performance underpins confidence in medium-term targets 2021-2026 outlook Metric On track Growth Sales Adj. operating profit Vaccines Specialty Medicines General Medicines Adj. operating margin Cash generated from Operations >5% CAGR >10% CAGR High-single-digit % CAGR Double digit % CAGR Broadly stable >30% by 2026 >£10bn by 2026 beyond 2026 driven by continued execution and pipeline progress GSK CAGR: Compound annual growth rate at constant exchange rates (CER) All guidance, outlooks, ambitions and expectations should be read together with the guidance, assumptions and cautionary statement in the Q2 2023 earnings release and the 2022 Annual Report. All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. CAGR is for the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and vaccine solutions are excluded from the above. 4#5Strongly focused on core therapy areas Developing pipeline through organic and business development progress GSK Infectious diseases Respiratory/ HIV Oncology immunology Arexvy MenABCWY Pneumococcal 24-valent mRNA Seasonal influenza/COVID-19 Shingrix GSK3943104 (Herpes simplex virus) GSK4348413 (gonorrhoea) gepotidacin Brexafemme Long-acting and ultra-long-acting N6LS (bNAb¹) 3rd generation INST12 Capsid inhibitor depemokimab camlipixant Nucala (COPD³) GSK4532990 (NASH4) GSK3858279 (osteoarthritis pain) GSK1070806 (atopic dermatitis) Jemperli Ojjaara Blenrep cobolimab CD226 axis tebipenem bepirovirsen Enabled by advanced technology and data platforms Note: select pipeline programmes shown 1. Broadly neutralising antibody 2. Integrase strand transfer inhibitor 3. Chronic obstructive pulmonary disease 4. Non-alcoholic steatohepatitis ST 5#6World leader in infectious diseases, £105bn market Transforming prevention and treatment of infectious diseases for billions of people 2023 progress and what's next Arexvy (RSV2, older adult) >£3bn PYS³ ⚫ First to receive approval • (US, EU, JP, UK) Regulatory decision on at risk 50-59 adults expected in 2024 Shingrix (shingles) >£4bn PYS³ ⚫ Partnership with Zhifei in China. . Life-cycle innovation work ongoing Influenza >£3bn PYS³ Multivalent mRNA vaccine candidate trials underway; phase II data H1 2024 Meningococcal disease £1-2bn PYS³ • MenABCWY US file submission expected in H1 2024 . Pneumococcal disease >₤4bn PYS³ 24v phase III start for adults and resumption of paediatric phase II trial in 2024 Bepirovirsen (Hepatitis B) >£2bn PYS³ • Exclusive license for JNJ-3989 to expand development B-WELL phase III data from 2025 Anti-infectives ~£2bn PYS3 . Preparing file submissions for gepotidacin ⚫ Phase III trial underway for tebipenem Herpes simplex virus Phase I/II data in 2024 GSK 1. Evaluate Pharma, May 2023 2. Respiratory syncytial virus 3. PYS: Non-risk adjusted peak year sales potential is subject to certain assumptions consistent with those for previous outlooks, ambitions and expectations 6#7Reshaping the HIV market, ~£7bn sales in 2026 Our commitments Pioneering innovation for treatment and prevention 6% to 8% sales CAGR 2021-26* • Dovato and cabotegravir drive growth via competitive execution . Cabotegravir replaces dolutegravir as foundational medicine 2026-31 LA¹ pipeline growth drivers Targeting four-monthly dosing for LA regimens in treatment and prevention Roadmap to extend to six-monthly dosing by end of decade ULA² PrEP Target product profiles 2026 Q4M file and launch 2027 2028-30 Q6M file and launch Q4M file and launch File and launch ULA treatment LA self-admin treatment Q6M file and launch GSK 1. Long-acting 2. Ultra-long-acting • Multiple pathways to deliver LA treatment and prevention * Forecasted CAGR is based on a constant exchange rate and includes an estimated ~£200m annual impact from 2025 of the US Inflation Reduction Act which has up to a one percentage point impact on the CAGR. Anticipated 2026 sales are based on 2023 exchange rates. 7#8Significant growth opportunities in respiratory High commercial synergy and capabilities supports future success Nucala (COPD) • First mAb² targeting IL-53 for COPD4 Pivotal data read outs • 212m COPD patients worldwide ~£0.5-1bn 37% have an eosinophilic phenotype in peak sales¹ depemokimab >£3bn in peak year sales¹ camlipixant >£2.5bn • • • • • Despite triple therapy utilization, 40% of total COPD patients still exacerbate 400k eligible population (US) First long-acting mAb targeting IL-5 for severe asthma, EGPA5, HES6, CRWNP7 315m asthma patients and 50-70% have eosinophilic asthma Only 28% of eligible US patients currently receive a biologic 57% of physicians likely to prescribe depemokimab in bio naïve patients? 66% likely to switch a patient from their current biologic to long acting 87% of patients would likely use based on physicians' recommendation 10 - High prevalence: 28m patients globally – significant burden and unmet medical need¹¹ ~70% of HCPs willing to try a new treatment 12 Phase III MATINEE (COPD) data expected H2 2024 Phase III SWIFT programme data expected H1 2024 Phase III CALM programme data expected H2 2025 • 3/4 of HCPs expect camlipixant to be best-in-disease 13 in peak year sales¹ • 85% prefer camlipixant due to low taste impact13 1. PYS: Non-risk adjusted peak year sales potential is subject to certain assumptions consistent with those for previous outlooks, ambitions and expectations 2. Monoclonal antibody 3. Interleukin 5 4. Chronic obstructive pulmonary disorder 5. Eosinophilic granulomatosis with polyangiitis 6. Hypereosinophilic syndrome 7. Chronic rhinosinusitis with nasal polyps 8. Heaney, LG et al. Chest, 2021. 160(3): p.814-830 9. Adelphi research 10. GSK 65pts Health Hub Voice 11. Song et al. Eur Resp J. 2015 and Liang et al. BMC Pulm Med. 2022 12. US RCC Market Opportunity Findings; N=661 HCPs; ZS Associates 13. IQVIA Market Landscape & Opportunity Assessment in Japan. October 2022, n=201.4. US RCC Rapid Quant Survey, N=120 HCPs (PULMS, ENTS and ALG), 2023 8#9Improving cancer survival and quality of life Initial focus on hematologic malignancies and gynaecologic cancers . Jemperli (dostarlimab) Ambition to be the backbone of our ongoing immuno-oncology research Combination treatment in endometrial cancer approved in US, EU with part one data to be presented in 2024 and positive part 2 data in house; monotherapy data is expected in 2027 Combination treatment with cobolimab, an anti-TIM3, in NSCLC, data expected 2024 Treatment in rectal cancer, data expected in 2027 • Ojjaara (momelotinib) Approved in the US as the first and only treatment indicated for MF2 patients with anaemia Nearly all MF patients are estimated to develop anaemia EU marketing authorisation expected early 2024 Potential to become a backbone therapy in MF due to differentiated MOA Combinations and future indications under evaluation • Zejula (niraparib) Assessing activity across multiple tumour types and in combination with other therapeutics Combination treatment in endometrial cancer positive data in house Combination treatment in ovarian cancer, data expected in 2024 Maintenance treatment in ovarian cancer, data expected in 2024 Maintenance treatment in NSCLC, data expected in 2024 Additional pipeline assets Exclusive license agreements with Hansoh for two novel antibody-drug conjugates for gynaecologic cancers and broader solid tumour indications Blenrep positive headline results for DREAMM-7 in second-line treatment for RRMM3; DREAMM-8 data in H2 2024 Cobolimab, an anti-TIM3 antagonist in phase III in combination with Jemperli for treatment of NSCLC Exploring novel combinations that act on all major targets of the CD226 axis; blocking these may help the immune system better target tumour cells GSK 1. Non-small cell lung cancer 2. Myelofibrosis 3. Relapse or refractory multiple myeloma#10Trust: Delivering health impact sustainably For health impact, shareholder returns and thriving people. Six areas of focus for ESG engagement Recent highlights Access Environment Global health and health security Diversity, equity and inclusion Product governance Ethical standards Low carbon version of Ventolin metered dose inhaler Phase III trials to start in 2024 on low carbon version of Ventolin which currently accounts for half of GSK's carbon footprint If successful, could reduce greenhouse gas emissions by ~90% Pharma industry leader on S&P Global Corporate Sustainability Assessment Annual evaluation of companies' ESG practices Pharma sector is one of the most competitive industries For 2023, GSK was named in leading position Net zero targets verified by the Science Based Target Initiative's (SBTi) Corporate Net-Zero Standard Targets include 80% reduction in greenhouse gas emissions by 2030 and 90% reduction by 2045 Aim to address the remaining emissions through high quality offsets GSK ESG: Environment, Social and Governance 10#11Investor roadmap highlights progress of key events Execution Pipeline Phase III and regulatory decisions² Q2 2023 Q2 and Half-year 2023 results Full-year 2023 upgraded guidance ✓ Therapy Area Strategy R&D priorities Arexvy US > > regulatory approval ☑ Arexvy second season data BELLUS Health, Inc. acquisition completed SCYNEXIS, Inc. exclusive license completed K Q3 2023 Q3 and Year-to-date 2023 results Arexvy RSV, ≥60 YOA (JP) Arexvy, RSV, 50-59 YoA Q4 2023 Full-year and Q4 2023 results Performance vs BIU 20211 Full-year 2024 guidance Apretude, HIV pre-exposure (EU) Vocabria, HIV treatment (CN) Ojjaara, MOMENTUM, myelofibrosis (US) Jemperli RUBY, 1L DMMR/MSI-H EC³ (US) >> > > > > H1 2024 Q1 2024 results Q2 and Half-year 2024 results Jemperli: RUBY, IL dMMR/MSI-H EC³ (EU) ☑ • Ojjaara: MOMENTUM, myelofibrosis (EU, JP) • Blenrep: DREAMM-7, 2L+ MM ✓ • gepotidacin: EAGLE-1, GC ° depemokimab: SWIFT-1/2, asthma • Jemperli: RUBY (Part 2), 1L EC³ ☑ • Jemperli: RUBY (Part 1) 1L OS4 EC3 ° Zejula: FIRST, IL maintenance OC ovarian cancer Capital Allocation Capital allocation R&D and BD priorities TA priorities く > > Full-year 2023 dividend declaration Roadshows Investor Engagement Meet the management, Meet the management, HIV Infectious Diseases Meet the management, Respiratory Meet the management, Oncology Medical congresses GSK 1. June 2021 Investor Update 2. Includes phase III data readouts and regulatory decisions with the applicable geography denoted in brackets 3. Endometrial cancer 5. cholestatic pruritus in primary biliary cholangitis • • H2 2024 Q3 and Year-to-date 2024 results Full-year and Q4 2024 results Performance vs BIU 20211 Guidance 2025 Arexvy: RSV, 50-59 YOA (US, EU, JP) Nucala: CRSwNP (JP) Nucala: severe asthma (CN) depemokimab: ANCHOR-1/2, CRSWNP Nucala MATINEE, COPD cobolimab: COSTAR, 2L NSCLC Blenrep: DREAMM-8, 2L MM Zejula: ZEAL, IL maintenance NSCLC linerixibat: GLISTEN, PBC5 Full-year 2024 dividend declaration 4. Overall survival population 11#12GSK Delivering strong and sustained momentum GSK Confident in delivering on our commitments to growth Innovation progress evident in core therapy areas with strong contributions from new product launches Performance underscores ability to sustain profitable growth through the decade and beyond 12#13GSK gsk.com